


CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

SR1020 (CONCENTRATE) // PRODUCED: DEC 08, 2021

CLIENT: CANNEUTICS, LLC // BATCH: PASS



MATRIX: CONCENTRATE
SAMPLE ID: NAL-211206-002
COLLECTED ON: DEC 06, 2021
RECEIVED ON: DEC 06, 2021
BATCH/SAMPLE SIZE: 750 G / 1.6 G
SAMPLED BY: KEVIN P MCALOON
RECEIVED BY: MIC LABEL

| CANNABINOID OVERVIEW | |
|----------------------------|---------------|
| CBD: | 29.4 % |
| CBDA: | 24.3 % |
| TOTAL CANNABINOIDS: | 58.8 % |

CULTIVATOR INFO

CULTIVATOR
KEVIN MCALOON
10 SUMMER ST
KENNEBUNK, MAINE 04043

LICENSE
CGR26593
MEDICINAL - CAREGIVER

MANUFACTURER INFO

MANUFACTURER
KEVIN MCALOON
10 SUMMER ST
KENNEBUNK, MAINE 04043

LICENSE
CGR26593
MEDICINAL - CAREGIVER

BATCH RESULT: PASS

| POTENCY | TESTED |
|-------------------|--------|
| METALS | PASS |
| MYCOTOXINS | PASS |
| PESTICIDES | PASS |
| SOLVENTS | PASS |
| TERPENES | TESTED |

CAN. 1: POTENCY & CANNABINOID PROFILE BY HPLC-UV
PREPARATION: DEC 07, 2021 // ANALYSIS: DEC 07, 2021

| ANALYTE | LIMIT | AMT | AMT | LOD/LOQ (%) | PASS/FAIL |
|---------|---------|-----------|-------------|-------------|-----------|
| CBC | 1.60 % | 16.0 mg/g | 0.139/0.696 | N/A | |
| CBCA | 0.788 % | 7.88 mg/g | 0.139/0.696 | N/A | |
| CBD | 29.4 % | 294 mg/g | 0.139/0.696 | N/A | |
| CBDA | 24.3 % | 243 mg/g | 0.139/0.696 | N/A | |
| CBDV | < LOQ | < LOQ | 0.139/0.696 | N/A | |
| CBDVA | < LOQ | < LOQ | 0.139/0.696 | N/A | |
| CBG | < LOQ | < LOQ | 0.139/0.696 | N/A | |
| CBGA | 0.979 % | 9.79 mg/g | 0.139/0.696 | N/A | |
| CBL | ND | ND | 0.139/0.696 | N/A | |
| CBLA | ND | ND | 0.139/0.696 | N/A | |
| CBN | ND | ND | 0.139/0.696 | N/A | |

| ANALYTE | LIMIT | AMT | AMT | LOD/LOQ (%) | PASS/FAIL |
|----------------------|--------|-----------|-------------|-------------|-----------|
| CBNA | | ND | ND | 0.139/0.696 | N/A |
| Δ ⁸ -THC | | ND | ND | 0.139/0.696 | N/A |
| Δ ⁹ -THC | 1.70 % | 17.0 mg/g | 0.139/0.696 | N/A | |
| Δ ¹⁰ -THC | | ND | ND | 0.139/0.696 | N/A |
| EXO-THC | | ND | ND | 0.139/0.696 | N/A |
| THCA | | ND | ND | 0.139/0.696 | N/A |
| THCV | < LOQ | < LOQ | 0.139/0.696 | N/A | |
| THCVA | | ND | ND | 0.139/0.696 | N/A |
| TOTAL THC ** | 1.70 % | 17.0 mg/g | | N/A | |
| TOTAL CBD ** | 50.7 % | 507 mg/g | | N/A | |

** TOTAL CBD = (CBDA X 0.877) + CBD
** TOTAL THC = (THCA X 0.877) + THC
Reported on an as received basis
1000 µg/g = 1 mg/g



RESULTS CERTIFIED BY:
BARRY CHAFFIN
COO, NOVA ANALYTIC LABS
DEC 08, 2021

RESULTS CERTIFIED BY:
GREG NEWLAND
CSO, NOVA ANALYTIC LABS
DEC 08, 2021

RESULTS CERTIFIED BY:
CHRIS ALTOMARE
CEO, NOVA ANALYTIC LABS
DEC 08, 2021

**TERPENES BY HEADSPACE GC-MS
PREPARATION: DEC 06, 2021 // ANALYSIS: DEC 07, 2021**

| ANALYTE | AMT | AMT | LOD/LOQ (mg/g) | PASS/FAIL |
|----------------------------|----------|------------|----------------|-----------|
| TOTAL TERPENES | 1.92 % | 19.2 mg/g | | N/A |
| β-CARYOPHYLLENE | 1.02 % | 10.2 mg/g | 0.148/0.297 | N/A |
| α-HUMULENE | 0.349 % | 3.49 mg/g | 0.148/0.297 | N/A |
| α-BISABOLOL | 0.161 % | 1.61 mg/g | 0.148/0.297 | N/A |
| LINALOOL | 0.138 % | 1.38 mg/g | 0.148/0.297 | N/A |
| D-LIMONENE | 0.104 % | 1.04 mg/g | 0.148/0.297 | N/A |
| CARYOPHYLLENE OXIDE | 0.0871 % | 0.871 mg/g | 0.148/0.297 | N/A |
| β-MYRCENE | 0.0571 % | 0.571 mg/g | 0.148/0.297 | N/A |
| α-OCIMENE | < LOQ | < LOQ | 0.0742/0.148 | N/A |
| TERPINOLENE | < LOQ | < LOQ | 0.148/0.297 | N/A |
| γ-TERPINENE | ND | ND | 0.148/0.297 | N/A |
| P-CYME | ND | ND | 0.148/0.297 | N/A |

| ANALYTE | AMT | AMT | LOD/LOQ (mg/g) | PASS/FAIL |
|-----------------------------|-----|-----|----------------|-----------|
| ISOPULEGOL | ND | ND | 0.148/0.297 | N/A |
| GERANIOL | ND | ND | 0.148/0.297 | N/A |
| CIS-NEROLIDOL | ND | ND | 0.148/0.297 | N/A |
| EUCALYPTOL | ND | ND | 0.148/0.297 | N/A |
| Δ³-CARENE | ND | ND | 0.148/0.297 | N/A |
| CAMPHENE | ND | ND | 0.148/0.297 | N/A |
| β-PINENE | ND | ND | 0.148/0.297 | N/A |
| β-OCIMENE | ND | ND | 0.0742/0.148 | N/A |
| α-TERPINENE | ND | ND | 0.148/0.297 | N/A |
| α-PINENE | ND | ND | 0.148/0.297 | N/A |
| TRANS-NEROLIDOL | ND | ND | 0.148/0.297 | N/A |

**RSOL.1: RESIDUAL SOLVENTS, POISONS AND TOXINS BY HEADSPACE GC-MS
PREPARATION: DEC 07, 2021 // ANALYSIS: DEC 08, 2021**

| ANALYTE | LIMIT | AMT (µg/g) | LOD/LOQ (µg/g) | PASS/FAIL |
|---------------------------|-----------|------------|----------------|-----------|
| 1,2-DICHLOROETHANE | 1 µg/g | ND | 0.704/1.41 | PASS |
| ACETONE | 5000 µg/g | < LOQ | 14.1/28.2 | PASS |
| ACETONITRILE | 410 µg/g | ND | 14.1/28.2 | PASS |
| BENZENE | 1 µg/g | ND | 0.704/1.41 | PASS |
| BUTANE | 5000 µg/g | ND | 1.41/3.52 | PASS |
| CHLOROFORM | 1 µg/g | ND | 0.704/1.41 | PASS |
| ETHANOL | 5000 µg/g | 121 | 14.1/28.2 | PASS |
| ETHYL ACETATE | 5000 µg/g | ND | 14.1/28.2 | PASS |
| ETHYLENE OXIDE | 1 µg/g | ND | 0.704/1.41 | PASS |
| ETHYL ETHER | 5000 µg/g | ND | 14.1/28.2 | PASS |
| HEPTANE | 5000 µg/g | ND | 14.1/28.2 | PASS |

| ANALYTE | LIMIT | AMT (µg/g) | LOD/LOQ (µg/g) | PASS/FAIL |
|---------------------------|-----------|------------|----------------|-----------|
| HEXANE | 290 µg/g | ND | 1.41/3.52 | PASS |
| ISOPROPYL ALCOHOL | 5000 µg/g | ND | 28.2/56.3 | PASS |
| METHANOL | 3000 µg/g | ND | 14.1/70.4 | PASS |
| METHYLENE CHLORIDE | 1 µg/g | ND | 0.704/1.41 | PASS |
| PENTANE | 5000 µg/g | ND | 14.1/28.2 | PASS |
| PROPANE | 5000 µg/g | ND | 28.2/56.3 | PASS |
| TOLUENE | 890 µg/g | ND | 7.04/14.1 | PASS |
| TRICHLOROETHYLENE | 1 µg/g | ND | 0.704/1.41 | PASS |
| O-XYLENE | 2170 µg/g | ND | 1.41/7.04 | PASS |
| P- AND M-XYLENE | 2170 µg/g | ND | 2.82/7.04 | PASS |
| TOTAL XYLENES | 2170 µg/g | ND | | PASS |

**PES.1: PESTICIDES, INSECTICIDES, FUNGICIDES AND GROWTH REGULATORS BY LC-MS/MS
PREPARATION: DEC 06, 2021 // ANALYSIS: DEC 07, 2021**

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|-------------------|------------|-------------|-----------------|-----------|
| BIFENTHRIN | 200 µg/kg | ND | 105/314 | PASS |
| CYFLUTHRIN | 1000 µg/kg | ND | 524/1570 | PASS |
| DAMINOZIDE | 1000 µg/kg | ND | 524/1570 | PASS |
| ETOXAZOLE | 200 µg/kg | ND | 105/314 | PASS |

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|-----------------------|-----------|-------------|-----------------|-----------|
| IMAZALIL | 200 µg/kg | ND | 105/314 | PASS |
| MYCLOBUTANIL | 200 µg/kg | ND | 105/314 | PASS |
| SPIROMESIFEN | 200 µg/kg | ND | 105/314 | PASS |
| TRIFLOXSTROBIN | 200 µg/kg | ND | 105/314 | PASS |

**MYC.1: MYCOTOXINS BY LC-HRMS
PREPARATION: DEC 07, 2021 // ANALYSIS: DEC 08, 2021**

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|---------------------|-------|-------------|-----------------|-----------|
| AFLATOXIN B1 | | ND | 0.376/1.13 | N/A |
| AFLATOXIN B2 | | ND | 1.13/1.88 | N/A |
| AFLATOXIN G1 | | ND | 0.376/1.13 | N/A |

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|-------------------------|----------|-------------|-----------------|-----------|
| AFLATOXIN G2 | | ND | 0.376/1.88 | N/A |
| OCHRATOXIN A | | ND | 0.751/2.25 | N/A |
| TOTAL MYCOTOXINS | 20 µg/kg | ND | | PASS |

**HME.1: HEAVY METALS BY ICP-MS
PREPARATION: DEC 06, 2021 // ANALYSIS: DEC 06, 2021**

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|----------------|-----------|-------------|-----------------|-----------|
| ARSENIC | 200 µg/kg | ND | 13.1/32.7 | PASS |
| CADMIUM | 200 µg/kg | ND | 13.1/32.7 | PASS |

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|----------------|-----------|-------------|-----------------|-----------|
| LEAD | 500 µg/kg | < LOQ | 13.1/39.2 | PASS |
| MERCURY | 100 µg/kg | ND | 13.1/26.2 | PASS |

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OMP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTE: NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED.

END OF REPORT

